Our Pricing

Wegovy Pill vs Injection: Which Is Better for You?

Choosing between wegovy pill vs injection UK options depends on your lifestyle, treatment goals, and personal preferences. Both formulations contain semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management, but they differ in administration method, dosing frequency, and how the medication is absorbed. At Cured Pharmacy, our UK-registered prescribers assess your individual circumstances to recommend the most suitable option, with transparent pricing from £79.00 for oral tablets and from £79.00 for injections.

Understanding Wegovy: Pill and Injection Formulations

Wegovy (semaglutide) is available in two distinct formulations in the UK: the traditional once-weekly subcutaneous injection and the newer oral tablet taken daily. Both contain the same active ingredient — semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone involved in appetite regulation and glucose metabolism [1]. The injectable form has been available since 2021, whilst the oral formulation received MHRA approval more recently, offering patients an alternative to needles.

The key difference lies not in efficacy but in pharmaceutical formulation. Injectable semaglutide delivers the medication directly into subcutaneous tissue, ensuring predictable absorption. Oral semaglutide uses a novel absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to facilitate uptake through the stomach lining, as peptide medications like semaglutide are normally broken down by digestive enzymes before reaching the bloodstream [2]. This technological innovation allows tablet users to achieve therapeutic blood levels comparable to injection users, though the dosing regimen differs.

Both formulations have demonstrated significant weight loss outcomes in clinical trials. The STEP programme evaluated injectable semaglutide, showing an average 14.9% body weight reduction over 68 weeks at the 2.4mg maintenance dose [1]. Oral semaglutide studies have shown similar efficacy when patients reach equivalent therapeutic doses, though the titration schedule and daily administration require consistent adherence to achieve optimal results.

Wegovy Injection: How It Works and Who It Suits

The Wegovy injection is administered once weekly using a pre-filled pen device. You inject the medication subcutaneously into your abdomen, thigh, or upper arm, rotating injection sites each week to minimise skin irritation. Treatment begins at 0.25mg weekly, gradually increasing every four weeks until reaching the maintenance dose of 2.4mg weekly, a titration schedule designed to minimise gastrointestinal side effects whilst allowing your body to adapt to the medication [1].

This formulation suits individuals who prefer a weekly routine rather than daily medication. Many patients find the once-weekly schedule easier to remember and integrate into their lifestyle, particularly those already managing multiple daily medications. The injection itself is relatively painless when administered correctly — the needle is fine-gauge and penetrates only the subcutaneous fat layer, not muscle tissue. Our clinical team provides detailed administration guidance during your consultation to ensure confidence with the injection technique.

Injectable semaglutide has the longest track record of real-world use in the UK, with extensive safety and efficacy data from both diabetes management (under the brand name Ozempic) and weight management contexts. This established evidence base gives prescribers confidence when recommending the injection to appropriate patients, particularly those with significant weight to lose or those who have struggled with previous weight management attempts [3].

Injection Technique and Storage Requirements

Wegovy pens must be stored in the refrigerator between 2°C and 8°C until first use, though they can remain at room temperature (up to 30°C) for up to 28 days once in use. Each pen contains four weekly doses, and you'll discard the pen after 28 days even if medication remains. Proper storage maintains medication stability and ensures consistent therapeutic effects throughout your treatment journey.

Wegovy Oral Tablets: Daily Convenience Without Needles

Wegovy oral tablets offer a needle-free alternative for patients who prefer not to inject or have needle phobia. The tablets are taken once daily on an empty stomach, at least 30 minutes before your first food, drink (other than water), or other oral medications of the day. This timing requirement is critical — the SNAC absorption enhancer works optimally in a fasting state, and food or other medications can significantly reduce semaglutide absorption [2].

The oral formulation follows a different dosing schedule than the injection. Treatment typically begins with lower-strength tablets, gradually increasing over several months to reach therapeutic doses. Because oral bioavailability is lower than injection (approximately 1% versus nearly 100%), the tablet strengths appear numerically different, but they're designed to achieve comparable blood levels of active semaglutide when taken as prescribed. Your UK prescriber will determine the appropriate starting dose and titration schedule based on your individual response and tolerability.

Patients who travel frequently, work irregular hours, or simply prefer oral medication often find the tablet formulation more convenient despite the daily dosing requirement. The tablets are compact, don't require refrigeration once dispensed, and eliminate concerns about needle disposal or injection site reactions. However, the strict fasting requirement and daily adherence demand consistency — missing doses or taking tablets with food can compromise treatment effectiveness.

Adherence Considerations for Daily Tablets

Success with oral semaglutide requires establishing a consistent morning routine. Many patients set a daily alarm, take their tablet immediately upon waking, then wait 30 minutes before breakfast. This routine becomes habitual within weeks, though shift workers or those with unpredictable schedules may find the weekly injection more practical. Your prescriber will discuss your daily routine during consultation to ensure the oral formulation aligns with your lifestyle.

Comparing Efficacy: Do Pills and Injections Work Equally Well?

Clinical trials demonstrate that both formulations can achieve significant weight loss when used as part of a comprehensive weight management programme including reduced-calorie diet and increased physical activity. The STEP 1 trial showed injectable semaglutide 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks [1]. Oral semaglutide studies, whilst using different trial designs, have shown comparable outcomes at equivalent therapeutic doses, with patients achieving sustained weight loss when adherent to the daily dosing regimen [2].

The key determinant of efficacy is not the delivery method but rather adherence, dose optimisation, and lifestyle modifications. Injectable semaglutide's once-weekly schedule may improve adherence for some patients, whilst others achieve better consistency with daily oral tablets that fit their established medication routines. Both formulations work through identical mechanisms — activating GLP-1 receptors in the brain to reduce appetite, slow gastric emptying, and improve satiety signals — so the therapeutic effect is fundamentally the same when adequate blood levels are maintained.

Your UK prescriber will consider several factors when recommending a formulation: your previous experience with medications, ability to maintain consistent routines, comfort with injections, and any gastrointestinal conditions that might affect oral absorption. Some patients start with one formulation and later switch to the other based on tolerability or lifestyle changes — both options remain available throughout your weight management journey, subject to ongoing prescriber assessment and clinical appropriateness.

Side Effects and Tolerability: Pill vs Injection Differences

Both formulations share common side effects related to GLP-1 receptor activation, primarily gastrointestinal symptoms including nausea, diarrhoea, constipation, and abdominal discomfort. These effects typically emerge during dose escalation and diminish as your body adapts to the medication. The gradual titration schedule for both formulations is specifically designed to minimise these symptoms whilst building therapeutic efficacy [1][3].

Some tolerability differences exist between formulations. Injectable semaglutide may cause injection site reactions — redness, itching, or mild swelling at the injection location — though these are generally minor and resolve within days. Oral semaglutide, due to its daily dosing and passage through the digestive system, may cause slightly different gastrointestinal symptom patterns in some patients, though clinical trial data shows similar overall tolerability profiles between formulations [2].

Serious side effects are rare but possible with both formulations. These include pancreatitis, gallbladder problems, and potential thyroid effects. Your prescriber will review your complete medical history during consultation to identify any contraindications. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use either formulation. Regular monitoring and open communication with your clinical team ensures any emerging concerns are addressed promptly, regardless of which formulation you're prescribed.

Managing Gastrointestinal Symptoms

Practical strategies can minimise side effects with either formulation: eating smaller, more frequent meals; avoiding high-fat foods that slow digestion further; staying well-hydrated; and not lying down immediately after eating. Your Cured Pharmacy clinical team provides personalised guidance on managing symptoms, and dose adjustments may be considered if side effects significantly impact your quality of life. Most patients find symptoms improve substantially after the first 4-8 weeks of treatment.

Cost, Availability, and Practical Considerations at Cured Pharmacy

At Cured Pharmacy, Wegovy oral tablets are available from £79.00 whilst Wegovy injections start from £79.00 both requiring a clinical assessment by our UK-registered prescribers. Pricing reflects the prescribed dose and treatment duration, with transparent costs shown before you complete your consultation. Unlike some providers, we display upfront pricing so you can make informed decisions about your weight management investment without hidden fees or surprise charges.

Both formulations require ongoing prescription renewal and clinical monitoring. Your prescriber will typically issue prescriptions for one to three months initially, with regular reviews to assess progress, tolerability, and ongoing clinical appropriateness. Weight loss medications are most effective when combined with lifestyle modifications, and our clinical team can provide guidance on nutrition and activity strategies that complement your pharmacological treatment.

Availability can fluctuate due to manufacturing capacity and demand, though Cured Pharmacy maintains relationships with multiple UK-licensed wholesalers to optimise stock continuity. If your preferred formulation is temporarily unavailable, our team will contact you to discuss alternatives, including switching between pill and injection forms if clinically appropriate. All medications dispensed are genuine UK-licensed products sourced through regulated supply chains, ensuring quality and safety standards are maintained throughout.

Starting Your Weight Loss Journey

Beginning treatment is straightforward: complete our free online consultation (typically under 3 minutes), where you'll provide medical history and weight management goals. A UK prescriber reviews your assessment, determines eligibility, and recommends the most suitable formulation based on your individual circumstances. If approved, your medication is dispensed by our GPhC-registered pharmacy and delivered in discreet packaging directly to your address. Our clinical team remains available throughout your treatment for questions, dose adjustments, or formulation changes as your needs evolve.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., Garvey, W. T., & OASIS 1 Investigators. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and physical activity levels. Wegovy (semaglutide) is indicated for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.